• Feb 19, 2025

Remitly (NASDAQ:RELY) Surprises With Q4 Sales, Stock Soars

Online money transfer platform Remitly (NASDAQ:RELY) beat Wall Street’s revenue expectations in Q4 CY2024, with sales up 32.9% year on year to $351.9 million. The company expects next quarter’s revenue to be around $346.5 million, close to analysts’ estimates. Its GAAP loss of $0.03 per share was 67.6% above analysts’ consensus estimates.

  • Feb 19, 2025

Herbalife (NYSE:HLF) Posts Better-Than-Expected Sales In Q4, Stock Jumps 13.7%

Health and wellness products company Herbalife (NYSE:HLF) reported Q4 CY2024 results exceeding the market’s revenue expectations, but sales were flat year on year at $1.21 billion. On the other hand, next quarter’s revenue guidance of $1.22 billion was less impressive, coming in 4.2% below analysts’ estimates. Its non-GAAP profit of $0.36 per share was significantly above analysts’ consensus estimates.

  • Feb 19, 2025

The Cheesecake Factory (NASDAQ:CAKE) Beats Q4 Sales Targets

Restaurant company Cheesecake Factory (NASDAQ:CAKE) beat Wall Street’s revenue expectations in Q4 CY2024, with sales up 5% year on year to $921 million. Its non-GAAP profit of $1.04 per share was 13.7% above analysts’ consensus estimates.

  • Feb 19, 2025

Mister Car Wash’s (NASDAQ:MCW) Q4 Sales Beat Estimates But Full-Year Sales Guidance Misses Expectations

Conveyorized car wash service company Mister Car Wash (NYSE:MCW) reported revenue ahead of Wall Street’s expectations in Q4 CY2024, with sales up 9.1% year on year to $251.2 million. On the other hand, the company’s full-year revenue guidance of $1.05 billion at the midpoint came in 2.3% below analysts’ estimates. Its non-GAAP profit of $0.09 per share was 25.1% above analysts’ consensus estimates.

  • Feb 19, 2025

Exact Sciences’s (NASDAQ:EXAS) Q4: Beats On Revenue

Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) announced better-than-expected revenue in Q4 CY2024, with sales up 10.3% year on year to $713.4 million. The company expects the full year’s revenue to be around $3.06 billion, close to analysts’ estimates. Its non-GAAP loss of $0.06 per share was 67.9% above analysts’ consensus estimates.

  • Feb 19, 2025

BioMarin Pharmaceutical (NASDAQ:BMRN) Reports Bullish Q4, Stock Soars

Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) reported revenue ahead of Wall Street’s expectations in Q4 CY2024, with sales up 15.6% year on year to $747.3 million. The company’s full-year revenue guidance of $3.15 billion at the midpoint came in 1.5% above analysts’ estimates. Its non-GAAP profit of $0.92 per share was 24.6% above analysts’ consensus estimates.

  • Feb 19, 2025

Grand Canyon Education’s (NASDAQ:LOPE) Q4 Sales Top Estimates, Quarterly Revenue Guidance Slightly Exceeds Expectations

Higher education company Grand Canyon Education (NASDAQ:LOPE) reported Q4 CY2024 results beating Wall Street’s revenue expectations, with sales up 5.1% year on year to $292.6 million. The company expects next quarter’s revenue to be around $287 million, coming in 0.5% above analysts’ estimates. Its GAAP profit of $2.84 per share was 1% below analysts’ consensus estimates.